310 related articles for article (PubMed ID: 28793964)
1. In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.
Karlowsky JA; Hackel MA; Bouchillon SK; Alder J; Sahm DF
Diagn Microbiol Infect Dis; 2017 Oct; 89(2):151-157. PubMed ID: 28793964
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China.
Biedenbach DJ; Bouchillon SK; Johnson B; Alder J; Sahm DF
Eur J Clin Microbiol Infect Dis; 2016 Dec; 35(12):1933-1939. PubMed ID: 27677280
[TBL] [Abstract][Full Text] [Related]
3. Activities of Tedizolid and Linezolid Determined by the Reference Broth Microdilution Method against 3,032 Gram-Positive Bacterial Isolates Collected in Asia-Pacific, Eastern Europe, and Latin American Countries in 2014.
Pfaller MA; Flamm RK; Jones RN; Farrell DJ; Mendes RE
Antimicrob Agents Chemother; 2016 Sep; 60(9):5393-9. PubMed ID: 27353270
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid.
Vanegas Múnera JM; Ocampo Ríos AM; Urrego DM; Jiménez Quiceno JN
Braz J Infect Dis; 2017; 21(5):493-499. PubMed ID: 28432878
[TBL] [Abstract][Full Text] [Related]
6. Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: an in vitro comparison.
Peñuelas M; Candel FJ; Lejarraga C; López-González L; Viñuela-Prieto JM; López de Mendoza D
Rev Esp Quimioter; 2016 Oct; 29(5):255-8. PubMed ID: 27374726
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tedizolid against methicillin-resistant Staphylococcus aureus and Peptostreptococcus anaerobius in thigh mixed-infection mouse model.
Yamagishi Y; Mikamo H; Kato H; Nishiyama N; Asai N; Koizumi Y; Sakanashi D; Suematsu H; Matsuura K; Hagihara M
J Infect Chemother; 2017 Jun; 23(6):368-373. PubMed ID: 28343752
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of Tedizolid phosphate against multidrug-resistant Streptococcus pneumoniae isolates from Asian countries.
Baek JY; Kang CI; Kim SH; Ko KS; Chung DR; Peck KR; Hsueh PR; Thamlikitkul V; So TM; Lee NY; Song JH;
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):218-20. PubMed ID: 27083121
[TBL] [Abstract][Full Text] [Related]
11. Results of the surveillance of Tedizolid activity and resistance program: in vitro susceptibility of gram-positive pathogens collected in 2011 and 2012 from the United States and Europe.
Sahm DF; Deane J; Bien PA; Locke JB; Zuill DE; Shaw KJ; Bartizal KF
Diagn Microbiol Infect Dis; 2015 Feb; 81(2):112-8. PubMed ID: 25488274
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe.
Bensaci M; Sahm D
Diagn Microbiol Infect Dis; 2017 Feb; 87(2):133-138. PubMed ID: 27866673
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections.
Littorin C; Hellmark B; Nilsdotter-Augustinsson Å; Söderquist B
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1549-1552. PubMed ID: 28326447
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tedizolid and other comparator drugs in methicillin-resistant Staphylococcus aureus isolates in skin and soft tissue infections in seven Colombian hospitals.
Leal AL; Ovalle MV; Cortés JA; Montañes AM; De la Rosa ZR; Rodríguez JY; Gualtero S; Ariza B; Sussman O; Torres MDP
Biomedica; 2018 Dec; 38(4):507-513. PubMed ID: 30653864
[TBL] [Abstract][Full Text] [Related]
15.
Brown-Elliott BA; Wallace RJ
J Clin Microbiol; 2017 Jun; 55(6):1747-1754. PubMed ID: 28330892
[TBL] [Abstract][Full Text] [Related]
16. Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate.
Xiao J; Gill C; Liang L; Liu J; Wu J; Feng HP; Flanagan S; Tan C; Flattery A
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373794
[TBL] [Abstract][Full Text] [Related]
17. Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins.
Thomson KS; Goering RV
Antimicrob Agents Chemother; 2013 Jun; 57(6):2892-5. PubMed ID: 23571550
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial Activity of Tedizolid, a Novel Oxazolidinone Against Methicillin-Resistant
Hasannejad-Bibalan M; Mojtahedi A; Biglari H; Halaji M; Sedigh Ebrahim-Saraie H
Microb Drug Resist; 2019 Nov; 25(9):1330-1337. PubMed ID: 31290721
[TBL] [Abstract][Full Text] [Related]
19. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.
Zurenko G; Bien P; Bensaci M; Patel HN; Thorne G
Ann Clin Microbiol Antimicrob; 2014 Sep; 13():46. PubMed ID: 25238753
[TBL] [Abstract][Full Text] [Related]
20. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
Rybak JM; Marx K; Martin CA
Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
